{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SBLOF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SBLOF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBLOF\",,,,,undefined,":{"symbol":"SBLOF","market":"US","secType":"STK","nameCN":"Shin Nippon Biomedical Laboratories Ltd.","latestPrice":9.36,"timestamp":1749672000000,"preClose":9.36,"halted":0,"volume":0,"delay":15,"floatShares":1556930,"shares":41631931,"eps":0.878369,"marketStatus":"Pre-Mkt","change":0,"latestTime":"06-11 16:00:00 EDT Delay","open":9.36,"high":9.36,"low":9.36,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.878369,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749735000000},"marketStatusCode":1,"adr":0,"exchange":"PINK LIMITED","adjPreClose":9.36,"volumeRatio":0.31152720761808633},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBLOF\",,,,,undefined,":{"symbol":"SBLOF","floatShares":1556930,"roa":"2.21%","roe":"13.10%","lyrEps":0.878369,"volumeRatio":0.31152720761808633,"shares":41631931,"dividePrice":0.3485,"high":9.36,"amplitude":0,"preClose":9.36,"low":9.36,"week52Low":9.36,"pbRate":"1.40","psRate":"1.72","week52High":9.82,"institutionHeld":0,"latestPrice":9.36,"eps":0.878369,"divideRate":0.037233,"volume":0,"delay":15,"ttmEps":0.878369,"open":9.36,"prevYearClose":9.82,"prevWeekClose":9.36,"prevMonthClose":9.36,"prevQuarterClose":9.51,"fiveDayClose":9.36,"twentyDayClose":9.36,"sixtyDayClose":9.51},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SBLOF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532164790","title":"Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2532164790","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532164790?lang=en_us&edition=fundamental","pubTime":"2025-05-01 08:00","pubTimestamp":1746057600,"startTime":"0","endTime":"0","summary":"Atzumi  nasal powder is the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults in an easy-to-use, easy-to-carrydevice.In clinical studies, Atzumi administration provided rapid and sustained DHE concentrations with lowvariability.DURHAM, N.C., April 30, 2025 /PRNewswire/ --Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. , today announced that the U.S. Food and Drug Administration  has approved a 505 New Drug Application  for Atzumi nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101.Atzumi is a proprietary drug device product incorporating both Satsuma's advanced nasal powder formulation of dihydroergotamine  administered via its unique nasal delivery device. The product is desi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/satsuma-pharmaceuticals-announces-u-fda-000000412.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/satsuma-pharmaceuticals-announces-u-fda-000000412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SBLOF","BK4121"],"gpt_icon":0},{"id":"2522527035","title":"SNBL and Tasso, Inc. to Establish Joint Venture in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2522527035","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522527035?lang=en_us&edition=fundamental","pubTime":"2025-03-28 07:50","pubTimestamp":1743119400,"startTime":"0","endTime":"0","summary":"TOKYO & KAGOSHIMA, Japan & SEATTLE, March 27, 2025----Tokyo & Kagoshima, Japan  / Seattle, Washington, USA : Shin Nippon Biomedical Laboratories, Ltd.  and Tasso, Inc., the Seattle-based leading provider of patient-centric, clinical grade blood collection solutions  hereby announce that they have agreed to establish a new joint venture company  for exclusive distribution of Tasso’s proprietary on-demand blood collection device in Japan.The JV has the exclusive right to sell Tasso products in Japan, and will manage and oversee the regulatory process, commercialization , and distribution of the device in Japan.\"As part of the SGG initiative, we aim to support the growth of Japanese companies that are aiming to enter the US market and US companies that are planning to enter the Japanese market, and to create new business opportunities for both sides. We believe that this JV is an initiative based on the SGG concept and will make a significant contribution to the improvement of clinical ex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/snbl-tasso-inc-establish-joint-235000135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TR","BK4185","JYNT","BK4121","SBLOF","BK4212","SGG"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SBLOF\",params:#limit:5,,,undefined,":[{"date":"2024-05-08","symbol":"SBLOF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715155200000,"name":null,"time":"","dateTimestamp":1715140800000,"actualEps":null},{"date":"2023-09-28","symbol":"SBLOF","amount":20,"announcedDate":"2023-07-19","type":"dividend","market":"US","newRecordDate":"2023-09-30","defaultRemindTime":1695907800000,"name":"Shin Nippon Biomedical Laboratories Ltd.","recordDate":"2023-11-30","payableDate":"2023-09-30","currency":"JPY","dateTimestamp":1695873600000,"payDate":"2023-11-30"},{"market":"US","date":"2023-03-30","symbol":"SBLOF","amount":30,"defaultRemindTime":1680183000000,"name":"Shin Nippon Biomedical Laboratories Ltd.","recordDate":"2023-06-29","payableDate":"2023-03-31","currency":"JPY","type":"dividend","dateTimestamp":1680148800000},{"date":"2022-10-31","symbol":"SBLOF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1667203200000,"name":null,"time":"Pre-Market","dateTimestamp":1667188800000,"actualEps":null},{"market":"US","date":"2022-03-30","symbol":"SBLOF","amount":10,"defaultRemindTime":1648647000000,"name":"Shin Nippon Biomedical Laboratories Ltd.","recordDate":"2022-06-30","payableDate":"2022-03-31","currency":"JPY","type":"dividend","dateTimestamp":1648612800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SBLOF\",market:\"US\",,,undefined,":[{"executeDate":"2022-03-30","recordDate":"2022-03-31","paymentDate":"2022-06-30","value":10,"currency":"JPY"},{"executeDate":"2023-03-30","recordDate":"2023-03-31","paymentDate":"2023-06-29","value":30,"currency":"JPY"},{"executeDate":"2023-09-28","recordDate":"2023-09-30","paymentDate":"2023-11-30","value":20,"currency":"JPY"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SBLOF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1741320000000}}}